Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Clinical trial NCT03377387 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03377387
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-13
- Primary completion
- 2026-12-01
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.